IL123010A - Pharmaceutical compositions of l-dopa ethyl ester - Google Patents

Pharmaceutical compositions of l-dopa ethyl ester

Info

Publication number
IL123010A
IL123010A IL12301096A IL12301096A IL123010A IL 123010 A IL123010 A IL 123010A IL 12301096 A IL12301096 A IL 12301096A IL 12301096 A IL12301096 A IL 12301096A IL 123010 A IL123010 A IL 123010A
Authority
IL
Israel
Prior art keywords
ethyl ester
pharmaceutical compositions
dopa ethyl
dopa
carrier
Prior art date
Application number
IL12301096A
Other languages
English (en)
Other versions
IL123010A0 (en
Original Assignee
Yissum Res Dev Co
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Teva Pharma filed Critical Yissum Res Dev Co
Publication of IL123010A0 publication Critical patent/IL123010A0/xx
Publication of IL123010A publication Critical patent/IL123010A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12301096A 1995-07-21 1996-07-18 Pharmaceutical compositions of l-dopa ethyl ester IL123010A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US136895P 1995-07-21 1995-07-21
PCT/IL1996/000058 WO1997003662A1 (en) 1995-07-21 1996-07-18 Pharmaceutical composition of l-dopa ethyl ester

Publications (2)

Publication Number Publication Date
IL123010A0 IL123010A0 (en) 1998-08-16
IL123010A true IL123010A (en) 2003-11-23

Family

ID=21695690

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12301096A IL123010A (en) 1995-07-21 1996-07-18 Pharmaceutical compositions of l-dopa ethyl ester

Country Status (12)

Country Link
US (1) US5840756A (de)
EP (1) EP0840603B1 (de)
JP (1) JPH11509547A (de)
AT (1) ATE223712T1 (de)
AU (1) AU6368596A (de)
CA (1) CA2227208A1 (de)
DE (1) DE69623634T2 (de)
DK (1) DK0840603T3 (de)
ES (1) ES2184881T3 (de)
IL (1) IL123010A (de)
PT (1) PT840603E (de)
WO (1) WO1997003662A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529407A (ja) * 1998-11-10 2002-09-10 テバ ファーマシューティカル インダストリーズ リミティド Ｌ−ｄｏｐａエチルエステル含有分散性組成物
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
GB0114198D0 (en) * 2001-06-11 2001-08-01 Syngenta Ltd Herbicidal composition
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
US20030135065A1 (en) * 2001-11-13 2003-07-17 Ramy Lidor-Hadas Process for the production of L-DOPA ethyl ester
AU2002340470A1 (en) 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
US20050113452A1 (en) * 2003-10-20 2005-05-26 Moshe Flashner-Barak Composition and dosage form for sustained effect of levodopa
US7342131B2 (en) * 2004-06-04 2008-03-11 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US20080193526A1 (en) * 2005-03-28 2008-08-14 Anders Pettersson Pharmaceutical Compositions Useful in the Treatment of Pain
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
EP1945188A2 (de) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa-zusammensetzung
EP1959948B1 (de) * 2005-12-05 2012-07-18 XenoPort, Inc. Levodopa-prodrug-mesylat, zusammensetzungen daraus und verwendungen davon
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
TW200843732A (en) * 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AU2008343787B2 (en) 2007-12-28 2014-01-30 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010047775A2 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
PL3054929T3 (pl) 2013-10-07 2021-05-31 Impax Laboratories, Llc Mukoadhezyjne preparaty lewodopy i / lub estrów lewodopy o kontrolowanym uwalnianiu oraz ich zastosowania
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
KR20230124622A (ko) 2020-12-22 2023-08-25 암닐 파마슈티컬스 엘엘씨 레보도파 투여 요법
WO2025075499A1 (en) 2023-10-02 2025-04-10 Universiteit Van Amsterdam Reducing dopamine feed-back inhibition in dopaminergic cells by tadalafil.
GB2644236A (en) 2024-09-24 2026-03-25 Novumgen Ltd Orodispersible tablet composition containing carbidopa and levodopa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
DK0840603T3 (da) 2003-01-20
DE69623634T2 (de) 2003-05-22
WO1997003662A1 (en) 1997-02-06
US5840756A (en) 1998-11-24
ATE223712T1 (de) 2002-09-15
DE69623634D1 (de) 2002-10-17
CA2227208A1 (en) 1997-02-06
ES2184881T3 (es) 2003-04-16
AU6368596A (en) 1997-02-18
PT840603E (pt) 2003-01-31
IL123010A0 (en) 1998-08-16
EP0840603A1 (de) 1998-05-13
JPH11509547A (ja) 1999-08-24
EP0840603B1 (de) 2002-09-11

Similar Documents

Publication Publication Date Title
IL123010A0 (en) Pharmaceutical compositions of L-DOPA ethyl ester
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
DE69831868D1 (en) Antithrombosemittel
IL133623A0 (en) Antithrombotic agents
GEP20022709B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
BG102172A (en) New stable medicamentous compositions for the preparation of propellant-free aerosols
HU9601846D0 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
IL133397A0 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
MXPA02001340A (es) Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
PL309282A1 (en) Application of 2-amino-6-n-propyl-amino- 4,5,6,7-tetrahydrobenzothiasole (pramipexol) as an antidepressant
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
AU6633596A (en) Improved therapeutic agents
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
TW334434B (en) Novel quinazoline compound and anti-tumor agent
AU7270798A (en) Antithrombotic agents
IL105276A (en) (S)-a-PHENYL- 2-PYRIDINEETHANAMINE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
NO982229D0 (no) Svovelholdige di-tert-butylfenol-forbindelser anvendbare som antiinflammatoriske midler
MD970244A (en) Dimer lysozime new application
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
FR2673375B1 (de)
TR199700963T1 (xx) Kardiyovask�ler hastal�klar�n tedavisi i�in aminotetralin t�revi.
BG102229A (en) Endothelium receptor antagonists
IL127154A0 (en) Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophoshoric acid
CA2129676A1 (en) Dextromethorphan Antitussive Compositions

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees